GEN Exclusives

More »

GEN News Highlights

Back to Item »

Patheon, Adventrx Ink Manufacturing Pact for Cardiovascular Candidate

Phase III trial with ANX-188 in patients with sickle cell disease will begin by year end.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

After Disney Measles Outbreak, Immunityland Less Magical

How should public health advocates counter anti-vaccination sentiment?